Horton Zachary, Schlatter Marc, Schultz Sarah
Helen Devos Children's Hospital, Grand Rapids Medical Education and Research Center, Michigan State University, Grand Rapids, MI 49503, USA.
Surg Oncol. 2007 Nov;16(3):205-13. doi: 10.1016/j.suronc.2007.07.005. Epub 2007 Aug 24.
Pediatric germ cell tumors are a diverse group of neoplasms with variable clinical behaviors, depending upon the age and site of presentation. Most result from sporadic mutations, although environmental exposures and other genetic aberrations may play a role. Platinum-based chemotherapy has dramatically improved the event-free and overall survival outcomes of pediatric patients with malignant germ cell tumors over the past two decades. Prognosis is dependent on tumor stage and location. Patients with gonadal germ cell tumors have at least a 95% 5-year survival for early stage disease and at least a 85% 5-year survival for advanced stages. In general, extragonadal germ cell tumors carry a poorer prognosis with mediastinal location having the worst outcomes (70% 4-year survival). Current trials are focused on maintaining similar excellent outcomes while reducing morbidity by reducing the dose and duration of chemotherapy. Cytogenetic research studies have found chromosomal aberrations specific to some of these tumors that may serve as prognosticators and even direct therapy.
小儿生殖细胞肿瘤是一组具有不同临床行为的肿瘤,其临床行为取决于发病年龄和部位。大多数是由散发性突变引起的,尽管环境暴露和其他基因畸变可能也起作用。在过去二十年中,基于铂的化疗显著改善了小儿恶性生殖细胞肿瘤患者的无事件生存率和总生存率。预后取决于肿瘤分期和位置。性腺生殖细胞肿瘤患者早期疾病的5年生存率至少为95%,晚期患者的5年生存率至少为85%。一般来说,性腺外生殖细胞肿瘤的预后较差,纵隔部位的预后最差(4年生存率为70%)。目前的试验重点是在保持相似的优异疗效的同时,通过减少化疗剂量和疗程来降低发病率。细胞遗传学研究发现了其中一些肿瘤特有的染色体畸变,这些畸变可能作为预后指标甚至指导治疗。